endo-3-naphthalen-2-yl-8-aza-bicyclo[3.2.1]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: endo-3-naphthalen-2-yl-8-aza-bicyclo[3.2.1]octane
• 英文别名: 3-(2-Naphthyl)-8-azabicyclo[3.2.1]octane；3-naphthalen-2-yl-8-azabicyclo[3.2.1]octane
• 化学式: C₁₇H₁₉N
• 分子量: 237.345
• InChiKey: TYANWMFRXUPZBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-naphthalen-2-yl-8-aza-bicyclo[3.2.1]oct-2-ene 在 palladium-carbon H2 作用下， 以 乙酸乙酯 为溶剂， 以62%的产率得到endo-3-naphthalen-2-yl-8-aza-bicyclo[3.2.1]octane
  参考文献：
  名称：

  Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression

  摘要：

  本发明包括式I1的化合物，其中A、X、n、Ar1和Ar2如本文所述。这些化合物可用于治疗抑郁症。本发明还包括含有这些化合物的配方，以及制备和使用本发明化合物的方法。

  公开号：

  US20030032645A1

文献信息

• Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110275595A1

  公开（公告）日：2011-11-10

  The present invention relates to compounds defined by formula I wherein the groups R 1 , Y 1 to Y 4 , V, W, and X are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由式I定义的化合物，其中R1，Y1至Y4，V，W和X基团的定义如权利要求书中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制的疾病，例如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20120115853A1

  公开（公告）日：2012-05-10

  The present invention relates to compounds defined by formula (I) wherein the groups R 1 and R 2 are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及公式(I)所定义的化合物，其中基团R1和R2如权利要求1所定义，具有有价值的药理活性。特别是，这些化合物是11β-羟类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION
  申请人：Wyeth

  公开号：EP1390364A1

  公开（公告）日：2004-02-25
• Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2318403B1

  公开（公告）日：2015-12-23
• UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2350068B1

  公开（公告）日：2017-08-30